Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PEG-Intron: Phase II data; Under review in U.S. and EU

ENZN partner Schering-Plough Corp. (SGP, Madison, N.J.) presented results of an open label Phase II dose-ranging study of PEG-Intron combined with its

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE